Repare Therapeutics (NASDAQ:RPTX) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Repare Therapeutics (NASDAQ:RPTX) in a report released on Wednesday morning, Benzinga reports. The firm currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for Repare Therapeutics’ Q3 2024 earnings at ($0.85) EPS, Q4 2024 earnings at ($0.85) EPS, FY2024 earnings at ($2.19) EPS, Q1 2025 earnings at ($0.89) EPS and FY2025 earnings at ($3.74) EPS.

Separately, Lifesci Capital raised shares of Repare Therapeutics to a strong-buy rating in a research report on Monday, July 29th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of Buy and an average target price of $17.33.

Repare Therapeutics Price Performance

RPTX stock opened at $2.82 on Wednesday. The firm’s fifty day simple moving average is $3.29 and its 200-day simple moving average is $3.90. The company has a market capitalization of $119.69 million, a P/E ratio of -2.56 and a beta of 0.71. Repare Therapeutics has a 12 month low of $2.71 and a 12 month high of $13.85.

Repare Therapeutics (NASDAQ:RPTX) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.03. The business had revenue of $1.07 million during the quarter, compared to analyst estimates of $4.02 million. Repare Therapeutics had a negative return on equity of 31.11% and a negative net margin of 99.76%. As a group, sell-side analysts forecast that Repare Therapeutics will post -2.31 earnings per share for the current year.

Institutional Trading of Repare Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of RPTX. XTX Topco Ltd acquired a new stake in Repare Therapeutics during the second quarter valued at approximately $110,000. Jump Financial LLC acquired a new position in Repare Therapeutics during the 4th quarter valued at about $289,000. Opaleye Management Inc. acquired a new position in shares of Repare Therapeutics during the first quarter worth approximately $318,000. Marshall Wace LLP bought a new position in shares of Repare Therapeutics in the second quarter worth $273,000. Finally, Bank of Montreal Can grew its position in Repare Therapeutics by 5.4% in the 2nd quarter. Bank of Montreal Can now owns 110,935 shares of the company’s stock valued at $366,000 after buying an additional 5,673 shares in the last quarter. 85.09% of the stock is owned by hedge funds and other institutional investors.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.